Top Industry Leaders in the Dyschromia Therapeutics Market
L'Oréal launched their SkinLightener Serum with new melanin-targeting technology claiming to reduce dark spots and even skin tone.
Johnson & Johnson introduced their Neutrogena® Rapid Tone Repair Moisturizer with Vitamin C and niacinamide for reducing hyperpigmentation and brightening skin.
Cynosure Received FDA clearance for their PicoSure® FOCUS lens for treating melasma and other pigmented lesions with improved precision and less side effects.
Alma Lasers introduced their Harmony XL PRO platform offering various laser and light options for treating different types of hyperpigmentation and melasma.
Lutronic Corporation Developed their Spectra™ Harmony laser system with multiple wavelengths for targeting various skin concerns, including dyschromia.
Galderma Announced the expansion of their Restylane® Contour portfolio with a new hyaluronic acid filler specifically designed for correcting hyperpigmentation on the back of hands.
Merz Aesthetics Received FDA approval for their Belotero® Revive filler with lidocaine for correcting wrinkles and improving skin tone, including reducing hyperpigmentation.
Allergan Aesthetics Continued research on their Juvederm® Vollure XC filler with a patented antioxidant complex, exploring its potential benefits for improving skin tone and reducing hyperpigmentation.
List of Dyschromia Therapeutics Key Companies in the Market
- Bayer AG
- ALLERGAN (AbbVie Inc.)
- Galderma S.A. (Nestle Skin Health S.A)
- SkinCeuticals
- Pierre Fabre
- EpiPharm AG
- RXi Pharmaceuticals Corporation
- Obagi Cosmeceuticals LLC (Obagi medical)
- Vivier Pharma
- Sirona Biochem's
- Menarini Group
